Terminal
Spotlight
Cashu Research

← Back to Terminal

Stocks
Healthcare
NASDAQ
VIR

Market Cap: $1.96B

VI

Vir Biotechnology, Inc.

VIR

NASDAQ (NASDAQ Global Select)USD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

News

Vir Biotechnology to Announce Q4 Results and Corporate Update on February 26, 2025

Vir Biotechnology Highlights Upcoming Corporate Update and Q4 Financial Results Vir Biotechnology, Inc. prepares to deliver a significant corporate update on February 26, 2025, alongside its financial…

Cashu Finance·over 1 year ago

Vir Biotechnology's VIR-5818 Shows Promise in Cancer Treatment with Phase 1 Data

Vir Biotechnology Reveals Promising Phase 1 Data for Novel T-Cell Engagers in Cancer Treatment Vir Biotechnology, Inc. has recently unveiled initial Phase 1 data for its innovative dual-masked T-cell…

Cashu Finance·almost 2 years ago

Vir Biotechnology Showcases Innovative Treatments at 43rd J.P. Morgan Healthcare Conference

Vir Biotechnology's Commitment to Innovative Treatments Highlighted at Upcoming Conference Vir Biotechnology Inc. is poised to showcase its commitment to advancing transformative medical solutions dur…

Cashu Finance·almost 2 years ago

Vir Biotechnology Secures Breakthrough Designations for Chronic Hepatitis Delta Treatments

Vir Biotechnology Advances Chronic Hepatitis Delta Treatments with Regulatory Designations Vir Biotechnology, Inc. has achieved significant milestones in the development of its therapies, tobevibart a…

Cashu Finance·almost 2 years ago

Vir Biotechnology Secures Breakthrough Designation for Chronic Hepatitis Delta Treatments

### Vir Biotechnology Advances Treatments for Chronic Hepatitis Delta Vir Biotechnology, Inc. announces a significant milestone in its fight against chronic hepatitis delta (CHD), as the U.S. Food and…

Cashu Finance·almost 2 years ago

Vir Biotechnology Showcases Innovations in Infectious Disease and Cancer at Health Conference

Vir Biotechnology's Commitment to Infectious Disease and Cancer Treatment Takes Center Stage at Health Conference Vir Biotechnology Inc. is poised to showcase its innovative approaches to combating se…

Cashu Finance·almost 2 years ago

Vir Biotechnology to Highlight Immune-Based Innovations at Evercore ISI HealthCONx Conference

Vir Biotechnology Showcases Leadership and Innovation at Upcoming Conference Vir Biotechnology Inc. prepares to highlight its ongoing commitment to advancing immune-based therapies at the 7th Annual E…

Cashu Finance·almost 2 years ago

Vir Biotechnology Secures EMA Support for Chronic Hepatitis Delta Treatments tobevibart and elebsiran

Vir Biotechnology Advances Treatments for Chronic Hepatitis Delta with EMA Support Vir Biotechnology, Inc. has received a significant endorsement from the European Medicines Agency (EMA) Committee for…

Cashu Finance·almost 2 years ago

Vir Biotechnology Advances Orphan Drug Designation for Chronic Hepatitis Delta Treatments

Vir Biotechnology Advances Orphan Drug Designation for Chronic Hepatitis Delta Treatments Vir Biotechnology, Inc. has garnered a positive opinion from the European Medicines Agency (EMA) Committee for…

Cashu Finance·almost 2 years ago

Vir Biotechnology Reports Promising Phase 2 Results for Chronic Hepatitis B Treatments

Vir Biotechnology Reports Promising Results for Chronic Hepatitis B Treatment Vir Biotechnology, Inc. announces positive results from the MARCH Phase 2 clinical study, focusing on the treatment of chr…

Cashu Finance·almost 2 years ago